<?xml version='1.0' encoding='utf-8'?>
<document id="29792394"><sentence text="Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia ."><entity charOffset="30-51" id="DDI-PubMed.29792394.s1.e0" text="candesartan cilexetil" /><entity charOffset="67-77" id="DDI-PubMed.29792394.s1.e1" text="paclitaxel" /><entity charOffset="82-93" id="DDI-PubMed.29792394.s1.e2" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.29792394.s1.e0" e2="DDI-PubMed.29792394.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29792394.s1.e0" e2="DDI-PubMed.29792394.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29792394.s1.e0" e2="DDI-PubMed.29792394.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29792394.s1.e1" e2="DDI-PubMed.29792394.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29792394.s1.e1" e2="DDI-PubMed.29792394.s1.e2" /></sentence><sentence text="Angiotensin receptor blockers (ARBs) are often used in patients on paclitaxel (PTX) and carboplatin combination (TC) therapy to treat hypertension caused by the co-administration of bevacizumab"><entity charOffset="0-11" id="DDI-PubMed.29792394.s2.e0" text="Angiotensin" /><entity charOffset="67-77" id="DDI-PubMed.29792394.s2.e1" text="paclitaxel" /><entity charOffset="79-82" id="DDI-PubMed.29792394.s2.e2" text="PTX" /><entity charOffset="88-99" id="DDI-PubMed.29792394.s2.e3" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e0" e2="DDI-PubMed.29792394.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e0" e2="DDI-PubMed.29792394.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e0" e2="DDI-PubMed.29792394.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e0" e2="DDI-PubMed.29792394.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e1" e2="DDI-PubMed.29792394.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e1" e2="DDI-PubMed.29792394.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e1" e2="DDI-PubMed.29792394.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e2" e2="DDI-PubMed.29792394.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29792394.s2.e2" e2="DDI-PubMed.29792394.s2.e3" /></sentence><sentence text=" The aim of this retrospective study was to analyze the association between co-administration of ARBs and the development of severe neutropenia in patients on TC therapy" /><sentence text="" /><sentence text="In this study, 211 concomitant medications were prescribed to 173 patients on TC therapy" /><sentence text=" 24 of those patients received ARBs" /><sentence text=" The incidences of neutropenia among those on various ARBs were compared" /><sentence text="" /><sentence text="Patients on candesartan cilexetil had the highest incidence of neutropenia compared to those on other concomitant medications, including other ARBs" /><sentence text=" Of 173 patients, 6 received candesartan cilexetil during the first cycle of TC therapy, and all 6 of them developed severe neutropenia" /><sentence text=" We noted that prior to TC therapy, there were no significant differences in age, serum albumin levels, neutrophil counts, liver injury marker, and renal function between the patients on candesartan cilexetil and those on other ARBs" /><sentence text="" /><sentence text="Our data suggest that a drug-drug interaction between candesartan cilexetil and TC therapy is probable" /><sentence text=" Unlike with other ARBs, the possible increased risk for development of severe neutropenia should be taken into account when prescribing candesartan cilexetil in combination with TC therapy" /><sentence text=" " /><sentence text="" /></document>